James Hellinger

2.4k total citations · 1 hit paper
30 papers, 1.8k citations indexed

About

James Hellinger is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, James Hellinger has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 12 papers in Virology and 12 papers in Epidemiology. Recurrent topics in James Hellinger's work include HIV/AIDS Research and Interventions (19 papers), HIV/AIDS drug development and treatment (14 papers) and HIV Research and Treatment (12 papers). James Hellinger is often cited by papers focused on HIV/AIDS Research and Interventions (19 papers), HIV/AIDS drug development and treatment (14 papers) and HIV Research and Treatment (12 papers). James Hellinger collaborates with scholars based in United States, United Kingdom and Vietnam. James Hellinger's co-authors include Kelly A. Gebo, John A. Fleishman, P. Todd Korthuis, Richard D. Moore, Philip Keiser, Richard Conviser, Paul Gaist, Fred J. Hellinger, Haya R. Rubin and William C. Mathews and has published in prestigious journals such as Science, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

James Hellinger

28 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1

1994 432 citations Richard Marlink, James Hellinger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Hellinger United States	19	1.4k	819	741	329	216	30	1.8k
George McSherry United States	22	1.6k 1.2×	821 1.0×	765 1.0×	307 0.9×	214 1.0×	52	1.9k
Katie R. Mollan United States	22	1.2k 0.9×	652 0.8×	431 0.6×	258 0.8×	157 0.7×	74	1.7k
Marc Lallemant Thailand	25	2.0k 1.5×	1.1k 1.4×	760 1.0×	404 1.2×	393 1.8×	123	2.4k
Kristine B. Patterson United States	26	1.7k 1.3×	1.0k 1.2×	655 0.9×	308 0.9×	245 1.1×	60	2.2k
Eduardo Sprinz Brazil	26	1.5k 1.1×	968 1.2×	503 0.7×	722 2.2×	150 0.7×	92	2.2k
Robert Downing Uganda	24	1.5k 1.1×	588 0.7×	729 1.0×	336 1.0×	242 1.1×	44	2.1k
Nagalingeswaran Kumarasamy India	25	1.3k 1.0×	720 0.9×	617 0.8×	287 0.9×	181 0.8×	97	1.8k
Jérôme Le Chenadec France	22	1.5k 1.1×	864 1.1×	644 0.9×	577 1.8×	255 1.2×	38	1.9k
Marcelo Losso Argentina	22	995 0.7×	684 0.8×	422 0.6×	253 0.8×	91 0.4×	62	1.4k
Shaffiq Essajee United States	24	1.3k 0.9×	547 0.7×	493 0.7×	216 0.7×	424 2.0×	62	1.6k

Countries citing papers authored by James Hellinger

Since Specialization

Citations

This map shows the geographic impact of James Hellinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Hellinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Hellinger more than expected).

Fields of papers citing papers by James Hellinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Hellinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Hellinger. The network helps show where James Hellinger may publish in the future.

Co-authorship network of co-authors of James Hellinger

This figure shows the co-authorship network connecting the top 25 collaborators of James Hellinger. A scholar is included among the top collaborators of James Hellinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Hellinger. James Hellinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fino, Nora F., Lesley A. Inker, Josef Coresh, et al.. (2025). Quantitative Analysis of a Novel Metabolite Panel to Estimate GFR (Panel eGFR) in Serum and Plasma Using LC-MS/MS. Clinical Chemistry. 71(12). 1269–1280.

Wyatt, Christina, Shiyuan Miao, Zipporah Krishnasami, et al.. (2020). Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. Kidney International Reports. 5(5). 734–737. 2 indexed citations

Inker, Lesley A., Christina Wyatt, Rebecca Creamer, et al.. (2012). Performance of Creatinine and Cystatin C GFR Estimating Equations in an HIV-Positive Population on Antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 61(3). 302–309. 68 indexed citations

Gebo, Kelly A., John A. Fleishman, Richard Conviser, et al.. (2010). Contemporary costs of HIV healthcare in the HAART era. AIDS. 24(17). 2705–2715. 141 indexed citations

Rhee, Martin S., et al.. (2010). Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double‐Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir). The Journal of Clinical Pharmacology. 50(4). 392–400. 6 indexed citations

Korthuis, P. Todd, Laurie Zephyrin, John A. Fleishman, et al.. (2008). Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use. AIDS Patient Care and STDs. 22(11). 859–867. 91 indexed citations

Korthuis, P. Todd, Somnath Saha, John A. Fleishman, et al.. (2008). Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care. Journal of General Internal Medicine. 23(12). 2046–2052. 17 indexed citations

Chander, Geetanjali, et al.. (2008). Alcohol use among HIV‐infected persons in care: results of a multi‐site survey^*. HIV Medicine. 9(4). 196–202. 70 indexed citations

Korthuis, P. Todd, Joshua Josephs, John A. Fleishman, et al.. (2008). Substance abuse treatment in human immunodeficiency virus: The role of patient–provider discussions. Journal of Substance Abuse Treatment. 35(3). 294–303. 34 indexed citations

10.

Himelhoch, Seth, Geetanjali Chander, John A. Fleishman, et al.. (2007). Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. General Hospital Psychiatry. 29(6). 518–525. 24 indexed citations

11.

Hellinger, James, et al.. (2005). Pilot Study of Saquinavir and Lopinavir/Ritonavir Twice Daily in Protease Inhibitor-Naive HIV-Positive Patients. HIV Clinical Trials. 6(2). 107–117. 10 indexed citations

12.

Fleishman, John A., Kelly A. Gebo, Erin D. Reilly, et al.. (2005). Hospital and Outpatient Health Services Utilization Among HIV-Infected Adults in Care 2000–2002. Medical Care. 43(9). III–40. 142 indexed citations

13.

Gebo, Kelly A., John A. Fleishman, Richard Conviser, et al.. (2004). Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001. JAIDS Journal of Acquired Immune Deficiency Syndromes. 38(1). 96–103. 240 indexed citations

14.

Cohen, Calvin, James Hellinger, Margaret M. Johnson, et al.. (2003). Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks. HIV Clinical Trials. 4(5). 347–357. 21 indexed citations

15.

Hellinger, James, Marika K. Iwane, Jeffery J. Smith, et al.. (2000). A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1. The Journal of Infectious Diseases. 181(2). 540–547. 18 indexed citations

16.

Hellinger, James, et al.. (2000). Efficacy of Nelfinavir in Patients Switched from Ritonavir/Saquinavir Combination Antiretroviral Therapy. HIV Clinical Trials. 1(2). 25–28. 2 indexed citations

17.

Cohen, Cyrille J., James Hellinger, John Day, et al.. (1996). Lack of Effect of Cimetidine on Lymphocyte Subsets in Patients Infected with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases. 23(5). 1049–1054. 1 indexed citations

18.

Flanigan, Timothy, Bharat Ramratnam, James Hellinger, et al.. (1996). Prospective trial of paromomycin for cryptosporidiosis in AIDS. The American Journal of Medicine. 100(3). 370–372. 24 indexed citations

19.

Hellinger, James, Richard Marlink, L. Kaptué, Léopold Zekeng, & Max Essex. (1990). Are tuberculosis patients a ‘sentinel’ population for HIV epidemic in Africa?. Transactions of the Royal Society of Tropical Medicine and Hygiene. 84(2). 292–292. 1 indexed citations

20.

Hellinger, James, et al.. (1967). [Animal experiment studies on autoantibody formation].. PubMed. 92(26a Pt 2). 1750–5.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact